|1.||Million, Mulugeta: 3 articles (07/2009 - 05/2002)|
|2.||Taché, Yvette: 3 articles (07/2009 - 05/2002)|
|3.||Adamik, A: 2 articles (06/2014 - 11/2008)|
|4.||Telegdy, G: 2 articles (06/2014 - 11/2008)|
|5.||Larauche, Muriel: 2 articles (07/2009 - 04/2008)|
|6.||Tachibana, Tetsuya: 2 articles (06/2009 - 02/2005)|
|7.||Harris, Ruth B S: 2 articles (12/2008 - 08/2008)|
|8.||Schäfer, Martin K-H: 2 articles (03/2005 - 12/2003)|
|9.||Mönnikes, Hubert: 2 articles (03/2005 - 12/2003)|
|10.||Kobelt, Peter: 2 articles (03/2005 - 12/2003)|
12/10/2010 - "Astressin blocked the UCN1-induced hyperthermia and reduced CRF-induced fever. "
11/01/2008 - "In order to study the possible role of CRH receptors, the animals were treated with a urocortins together with the urocortin receptor inhibitors CRF 9-41, antalarmin and astressin 2B to influence the action of urocortins in initiating hyperthermia. "
06/01/2014 - "For an investigation of the possible role of receptors in mediating hyperthermia, the animals were treated simultaneously with CRF 9-41 and antalarmin, a CRH1 receptor inhibitors, astressin 2B, a CRH2 receptor antagonist, haloperidol a dopamine receptor antagonist, atropine a muscarinic cholinergic receptor antagonist, noraminophenazone a cyclooxygenase inhibitor or isatin, a prostaglandin receptor antagonist. "
04/01/2008 - "Chronic subcutaneous delivery of astressin reduced the stress-induced visceral hyperalgesia to baseline at all distension pressures. "
07/01/2009 - "The CRF antagonist astressin (10 mug/kg ip) abolished ip cortagine-induced hyperalgesia whereas injected icv it had no effect. "
01/01/2008 - "ACTH(11-24) and astressin blocked EA anti-edema but not EA anti-hyperalgesia. "
09/01/2013 - "Pretreatment with the CRF2 receptor antagonist astressin 2B, but not the CRF1 receptor antagonist NBI-35965, attenuated this hyperalgesia. "
06/01/2009 - "In Experiment 4, astressin (a non-selective corticotrophin-releasing factor [CRF] receptor antagonist) prevented SCP-induced anorexia in broiler-type chicks. "
12/01/2008 - "This effect was abolished by pretreatment with a non-selective CRF receptor antagonist, astressin, suggesting that the effect of alpha-MSH-induced anorexia was mediated by a CRF receptor. "
02/15/2005 - "Co-injection of a CRF receptor antagonist, astressin, attenuated ghrelin-induced plasma corticosterone increase and anorexia. "
|5.||Ganglion Cysts (Ganglion)
05/01/2002 - "The CRF(1)/CRF(2) antagonist astressin (33 microg/kg ip) and the selective CRF(1) antagonist CP-154,526 (20 mg/kg sc) prevented intraperitoneal CRF-induced Fos expression in the proximal colon (number of Fos-IR cells/ganglion: 2.7 +/- 1.2 and 1.0 +/- 1.0, respectively), whereas atropine (1 mg/kg sc) had no effect. "
05/21/2004 - "The effects of ES (0.3-0.5 mA) or the central administration of corticotropin-releasing factor (CRF; astressin, 10 microg/kg) or cholecystokinin (CCKB; 20 microg/kg) receptor antagonists and peripheral glucocorticoid receptor (RU-486; 10 mg/kg) or ganglion (hexamethonium; 15 mg/kg) blockers on TNBS-induced colitis were studied by the assessment of macroscopic score, histological analysis and tissue myeloperoxidase activity. "
|1.||Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)
|4.||Kainic Acid (Kainate)
|7.||Adrenocorticotropic Hormone (ACTH)
|8.||CRF receptor type 2
|9.||CRF receptor type 1